Developer docs
API playgroundTry for free, no card

Search company profiles

Autotelic

Full company profile

uuid000aaw3

Namestring
Autotelic
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Autotelic is a privately held, for-profit biotechnology company founded in 2013 and headquartered in City of Industry, California. According to its stated description, the company applies therapeutic drug monitoring (TDM) — the measurement of drug concentrations in biological samples — to improve the development of therapeutics, presumably informing dosing, efficacy, and safety decisions during preclinical or clinical-stage development. The company operates with a staff of 11–50 employees and is led by CEO Vuong Trieu, founder Stephen Gibb, co-founder and Chief Business Officer Chulho Park, and Osmond D'Cruz as Director of Drug Safety.

The presence of a dedicated drug safety function and a CBO is consistent with a development-stage focus on therapeutic candidates, but no specific pipeline assets, indications, platform technology details, or clinical milestones are disclosed in available sources. The corporate website at autotelicinc.com is non-functional, displaying only empty Apache directory index pages with no product, pipeline, or company information. The technology stack, pricing model, distribution channels, customer segments, and GTM motion are not documented in the provided data.

Autotelic's external capital formation appears minimal based on disclosed information — a single recorded financing of $150,000 in December 2014 with unidentified investors, and no subsequent rounds, pharmaceutical partnerships, or licensing arrangements reported. No customers, pricing, or revenue figures are publicly disclosed. A 2026-dated source references an entity called 'Autotelic Ventures' co-leading a $5 million investment in the game studio Odd Meter, but the relationship between Autotelic Ventures and Autotelic (the biotech) is not clarified in available materials, leaving the overall business model, commercial trajectory, and entity structure materially unconfirmed.

Short descriptiontext

Autotelic is a private biotech company founded in 2013 that applies therapeutic drug monitoring to enhance therapeutic drug development. The City of Industry, California-based firm employs 11–50 staff and has minimal disclosed external funding and no commercial products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCity Of Industry, United States
HQ citystring
City Of Industry
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
therapeutic drug monitoring, drug development services, clinical pharmacology, biotech therapeutics, pharmacokinetic analysis
Industry3 codes
PRIMARYHLAFAMAF
Toxicology & Therapeutic Drug Monitoring Laboratories
SECONDARYHLACAOAI
Clinical Trial Analytics, Risk-Based Monitoring (RBM) & Quality Management
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAMADAG
Toxicology & Therapeutic Drug Monitoring
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Diagnostics (Labs & Imaging)
NAICS code2 codes
  • Medical Laboratories621511
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Development Services
No data
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Autotelic applies therapeutic drug monitoring (TDM) to support and enhance the development of therapeutics. The company's work centers on pharmacokinetic and pharmacodynamic assessment to inform dosing, safety, and efficacy decisions during drug development programs for partners in the pharmaceutical and biotechnology sectors.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Therapeutic Drug Monitoring for Therapeutic Development
CategoryClinical / Drug Development Services
Description

Application of therapeutic drug monitoring (TDM) approaches — including pharmacokinetic analysis and drug-level measurement — to support the development, dosing optimization, and safety evaluation of new therapeutics. Targeted at pharmaceutical and biotechnology companies developing drug candidates.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Eurofins is a global laboratory services group with significant pharmacokinetics, bioanalytical, and therapeutic drug monitoring capabilities serving pharma R&D. It competes with Autotelic by offering TDM and PK/PD assay work as part of a broad life sciences testing portfolio, often at greater scale.

TypeBroad incumbent
Description

Labcorp's drug development arm provides central laboratory services including bioanalytical and TDM support for clinical trials. It is a broad incumbent that bundles TDM with full-service CRO capabilities, putting pricing pressure on specialists like Autotelic.

TypeBroad incumbent
Description

Charles River offers bioanalytical, pharmacokinetic, and drug safety testing services that overlap with Autotelic's TDM-enabled drug development thesis. As a large preclinical CRO, it competes for the same pharma R&D budgets, particularly on the nonclinical and IND-enabling side.

TypeBroad incumbent
Description

ICON is a global CRO with central labs and bioanalytical services supporting clinical pharmacology and TDM for trials. It is a broad incumbent that can offer sponsors an integrated lab + clinical operations package Autotelic cannot match.

TypeDirect peer
Description

ARUP is a reference laboratory known for esoteric and specialized clinical testing, including therapeutic drug monitoring and toxicology. It is one of the closest direct comparables on TDM lab service capability, with a similar focus on complex, niche assay work for healthcare providers and researchers.

TypeDirect peer
Description

Saladax develops and commercializes proprietary TDM assays (e.g., for chemotherapeutics and antipsychotics) used by hospitals and clinical trial sponsors. It is a direct niche peer, focused on commercializing TDM technology in much the same therapeutic-development orbit as Autotelic.

7Absorption Systems
TypeDirect peer
Description

Absorption Systems (now part of Eurofins) specialized in preclinical ADME/PK and bioanalytical services for drug development, including TDM-style assay work for small molecules and biologics. It is a closely aligned specialist peer serving similar biotech and pharma R&D customers.

8Alturas Analytics
TypeDirect peer
Description

Alturas Analytics is a bioanalytical CRO providing LC-MS/MS-based PK, TK, and bioequivalence assay services for drug development programs. It is a small specialist peer comparable to Autotelic in size and therapeutic-monitoring-focused value proposition.

TypeEmerging player
Description

Syneos offers clinical pharmacology unit services with bioanalytical and PK sampling tightly integrated with early-phase trials. It is an emerging peer at the TDM-and-clinical-trial intersection, competing for the same outsourced drug-development work.

TypeBroad incumbent
Description

PPD, now part of Thermo Fisher, runs global central labs and bioanalytical services that include therapeutic drug monitoring for clinical trials. As a broad incumbent, it competes for the same pharma R&D TDM contracts as Autotelic.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Autotelic

Drug Development Servicesautotelicinc.com

Autotelic is a private biotech company founded in 2013 that applies therapeutic drug monitoring to enhance therapeutic drug development. The City of Industry, California-based firm employs 11–50 staff and has minimal disclosed external funding and no commercial products.

What Autotelic does

Autotelic is a privately held, for-profit biotechnology company founded in 2013 and headquartered in City of Industry, California. According to its stated description, the company applies therapeutic drug monitoring (TDM) — the measurement of drug concentrations in biological samples — to improve the development of therapeutics, presumably informing dosing, efficacy, and safety decisions during preclinical or clinical-stage development. The company operates with a staff of 11–50 employees and is led by CEO Vuong Trieu, founder Stephen Gibb, co-founder and Chief Business Officer Chulho Park, and Osmond D'Cruz as Director of Drug Safety.

The presence of a dedicated drug safety function and a CBO is consistent with a development-stage focus on therapeutic candidates, but no specific pipeline assets, indications, platform technology details, or clinical milestones are disclosed in available sources. The corporate website at autotelicinc.com is non-functional, displaying only empty Apache directory index pages with no product, pipeline, or company information. The technology stack, pricing model, distribution channels, customer segments, and GTM motion are not documented in the provided data.

Autotelic's external capital formation appears minimal based on disclosed information — a single recorded financing of $150,000 in December 2014 with unidentified investors, and no subsequent rounds, pharmaceutical partnerships, or licensing arrangements reported. No customers, pricing, or revenue figures are publicly disclosed. A 2026-dated source references an entity called 'Autotelic Ventures' co-leading a $5 million investment in the game studio Odd Meter, but the relationship between Autotelic Ventures and Autotelic (the biotech) is not clarified in available materials, leaving the overall business model, commercial trajectory, and entity structure materially unconfirmed.

Autotelic firmographics

Firmographics
Name
Autotelic
Website
https://autotelicinc.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Autotelic is a private biotech company founded in 2013 that applies therapeutic drug monitoring to enhance therapeutic drug development. The City of Industry, California-based firm employs 11–50 staff and has minimal disclosed external funding and no commercial products.
Ownership category
akta.pro rank

Autotelic industry classification

Industry
Product category
Drug Development Services
NAICS
Medical Laboratories (621511), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAFAMAF
Toxicology & Therapeutic Drug Monitoring Laboratories
SECONDARYHLACAOAI
Clinical Trial Analytics, Risk-Based Monitoring (RBM) & Quality Management
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAMADAG
Toxicology & Therapeutic Drug Monitoring
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Diagnostics (Labs & Imaging)

Keywords

  • Therapeutic drug monitoring
  • Drug development services
  • Clinical pharmacology
  • Biotech therapeutics
  • Pharmacokinetic analysis

Where Autotelic is headquartered

Location

Headquarters

HQ city
City Of Industry
HQ country
United States
HQ region
North America

Markets served

Autotelic business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Autotelic product offering

Product offering

Core offering

Autotelic applies therapeutic drug monitoring (TDM) to support and enhance the development of therapeutics. The company's work centers on pharmacokinetic and pharmacodynamic assessment to inform dosing, safety, and efficacy decisions during drug development programs for partners in the pharmaceutical and biotechnology sectors.

Differentiator

Problem solved

Functional benefit

Products and services

  • Therapeutic Drug Monitoring for Therapeutic Development Application of therapeutic drug monitoring (TDM) approaches — including pharmacokinetic analysis and drug-level measurement — to support the development, dosing optimization, and safety evaluation of new therapeutics. Targeted at pharmaceutical and biotechnology companies developing drug candidates.

Companies that use Autotelic

Customer profile

Ideal customer profiles1 record

Autotelic technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Autotelic partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves1 record

Expansion highlights2 records

Autotelic competitors and assessment

Company assessment

Broad incumbents

  • Eurofins Scientific: Eurofins is a global laboratory services group with significant pharmacokinetics, bioanalytical, and therapeutic drug monitoring capabilities serving pharma R&D. It competes with Autotelic by offering TDM and PK/PD assay work as part of a broad life sciences testing portfolio, often at greater scale.
  • Labcorp Drug Development (formerly Covance): Labcorp's drug development arm provides central laboratory services including bioanalytical and TDM support for clinical trials. It is a broad incumbent that bundles TDM with full-service CRO capabilities, putting pricing pressure on specialists like Autotelic.
  • Charles River Laboratories: Charles River offers bioanalytical, pharmacokinetic, and drug safety testing services that overlap with Autotelic's TDM-enabled drug development thesis. As a large preclinical CRO, it competes for the same pharma R&D budgets, particularly on the nonclinical and IND-enabling side.
  • ICON plc (including PRA Health and MolecularMD): ICON is a global CRO with central labs and bioanalytical services supporting clinical pharmacology and TDM for trials. It is a broad incumbent that can offer sponsors an integrated lab + clinical operations package Autotelic cannot match.
  • PPD (Thermo Fisher Scientific): PPD, now part of Thermo Fisher, runs global central labs and bioanalytical services that include therapeutic drug monitoring for clinical trials. As a broad incumbent, it competes for the same pharma R&D TDM contracts as Autotelic.

Direct peers

  • ARUP Laboratories: ARUP is a reference laboratory known for esoteric and specialized clinical testing, including therapeutic drug monitoring and toxicology. It is one of the closest direct comparables on TDM lab service capability, with a similar focus on complex, niche assay work for healthcare providers and researchers.
  • Saladax Biomedical: Saladax develops and commercializes proprietary TDM assays (e.g., for chemotherapeutics and antipsychotics) used by hospitals and clinical trial sponsors. It is a direct niche peer, focused on commercializing TDM technology in much the same therapeutic-development orbit as Autotelic.
  • Absorption Systems: Absorption Systems (now part of Eurofins) specialized in preclinical ADME/PK and bioanalytical services for drug development, including TDM-style assay work for small molecules and biologics. It is a closely aligned specialist peer serving similar biotech and pharma R&D customers.
  • Alturas Analytics: Alturas Analytics is a bioanalytical CRO providing LC-MS/MS-based PK, TK, and bioequivalence assay services for drug development programs. It is a small specialist peer comparable to Autotelic in size and therapeutic-monitoring-focused value proposition.

Emerging players

  • Syneos Health (clinical pharmacology unit): Syneos offers clinical pharmacology unit services with bioanalytical and PK sampling tightly integrated with early-phase trials. It is an emerging peer at the TDM-and-clinical-trial intersection, competing for the same outsourced drug-development work.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

Autotelic financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Autotelic leadership team

Management profile

Number of profiles

Profiles4 records

Autotelic funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Autotelic M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Autotelic

What does Autotelic do?

Autotelic applies therapeutic drug monitoring (TDM) to support and enhance the development of therapeutics. The company's work centers on pharmacokinetic and pharmacodynamic assessment to inform dosing, safety, and efficacy decisions during drug development programs for partners in the pharmaceutical and biotechnology sectors.

When was Autotelic founded?

Autotelic was founded in 2013. It employs 11 to 50 people.

Where is Autotelic based?

Autotelic is headquartered in City Of Industry, United States, in the North America region.

Who are Autotelic's main competitors?

Broad incumbents on record are Eurofins Scientific, Labcorp Drug Development (formerly Covance), Charles River Laboratories, ICON plc (including PRA Health and MolecularMD) and PPD (Thermo Fisher Scientific). Direct peers are ARUP Laboratories, Saladax Biomedical, Absorption Systems and Alturas Analytics. Syneos Health (clinical pharmacology unit) is listed as an emerging player.

Does Autotelic have an API?

No public API is recorded for Autotelic.

What industry is Autotelic in?

Autotelic's product category is Drug Development Services. Its primary akta.pro industry code is HLAFAMAF, Toxicology & Therapeutic Drug Monitoring Laboratories, with a secondary code of HLACAOAI, Clinical Trial Analytics, Risk-Based Monitoring (RBM) & Quality Management. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals